Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,136 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,136 Papers indexed
1,440 Papers AI scored
40,136 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-06 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40136 results
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 64.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
A single-center retrospective study investigating use of dietetic interventions and changes in nutritional intake and weight in children receiving proton beam therapy.
PMID 41655313 Published: 2026-01-09 Ingested: 2026-08-02 12:06 AM Nutrition (Burbank, Los Angeles County, Calif.)
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 51.7; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 79.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 51.7; sample size: 90.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 44.2; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

B
[Treatment of pediatric chronic myeloid leukemia].
PMID 41034077 Published: 2025-01-01 Ingested: 2026-08-02 12:03 AM [Rinsho ketsueki] The Japanese journal of clinical hematology
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 34.2; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

B
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.
PMID 40974099 Published: 2025-09-19 Ingested: 2026-08-02 12:05 AM Pediatric blood & cancer
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
PMID 40448577 Published: 2025-05-31 Ingested: 2026-08-02 12:04 AM Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 64.2; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Safety and Efficacy of Selective Internal Radiation Therapy for Portal Vein Tumour Thrombus in Advanced Hepatocellular Carcinoma: A Single-Centre Experience in Australia.
PMID 39913851 Published: 2025-02-06 Ingested: 2026-08-02 12:03 AM Journal of medical imaging and radiation oncology
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

B
Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma.
PMID 39332513 Published: 2024-09-25 Ingested: 2026-08-02 12:02 AM American journal of ophthalmology
AI -
Standard 71.34
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 591 of 3345
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic